Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Halozyme to Report Second Quarter 2026 Financial and Operating Results PR Newswire - Thu Jul 23, 7:30AM CDT

SAN DIEGO , July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday,...

HALO : 80.84 (+3.88%)
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology PR Newswire - Mon Jul 20, 7:00AM CDT

Agreement provides Incyte the rights to develop and commercialize ENHANZE ® with its mutCALR development program and an option to nominate up to two additional targets

INCY : 116.69 (+0.78%)
HALO : 80.84 (+3.88%)
NX
1 Value Stock Worth Investigating and 2 Facing Headwinds StockStory - Tue Jul 14, 11:38PM CDT

1 Value Stock Worth Investigating and 2 Facing Headwinds

ASLE : 6.18 (+1.48%)
NX : 18.26 (-1.14%)
HALO : 80.84 (+3.88%)
HALO
2 Reasons to Like HALO and 1 to Stay Skeptical StockStory - Thu Jul 9, 11:02PM CDT

2 Reasons to Like HALO and 1 to Stay Skeptical

HALO : 80.84 (+3.88%)
ACT
1 Surging Stock for Long-Term Investors and 2 We Brush Off StockStory - Tue Jun 30, 11:36PM CDT

1 Surging Stock for Long-Term Investors and 2 We Brush Off

ACT : 45.97 (+0.44%)
HALO : 80.84 (+3.88%)
CLMT : 42.82 (-2.99%)
UPST
2 Profitable Stocks Worth Your Attention and 1 We Question StockStory - Wed Jun 17, 11:39PM CDT

2 Profitable Stocks Worth Your Attention and 1 We Question

ADM : 86.35 (-1.11%)
UPST : 27.59 (-3.67%)
HALO : 80.84 (+3.88%)
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 PR Newswire - Mon Jun 15, 5:00AM CDT

SAN DIEGO , June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact...

HALO : 80.84 (+3.88%)
HALO
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today StockStory - Wed Jun 3, 1:35PM CDT

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

HALO : 80.84 (+3.88%)
HALO
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions StockStory - Mon May 18, 12:31AM CDT

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

HALO : 80.84 (+3.88%)
TOST
3 Growth Stocks Set to Flourish StockStory - Thu May 14, 11:32PM CDT

3 Growth Stocks Set to Flourish

CECO : 79.59 (-2.73%)
TOST : 28.40 (-2.77%)
HALO : 80.84 (+3.88%)

Barchart Exclusives

CapEx Fears Eclipse Alphabet’s Strong Q2, but GOOGL Stock Still Looks Attractive Barchart - Thu Jul 23, 6:30PM CDT
While GOOGL stock could remain volatile as investors digest elevated spending, Alphabet remains well positioned to benefit from the accelerating AI investment cycle. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.